These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 15155212)

  • 1. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
    González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
    Kretschmar M; Nichterlein T; Hannak D; Hof H
    Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
    Clemons KV; Stevens DA
    J Antimicrob Chemother; 1992 Sep; 30(3):353-63. PubMed ID: 1452501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1829-33. PubMed ID: 1952853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis.
    Allendoerfer R; Yates RR; Sun SH; Graybill JR
    J Med Vet Mycol; 1992; 30(5):377-84. PubMed ID: 1469539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on fungal infections.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Jul; 3(7):27-32. PubMed ID: 11364470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of lipid formulations of amphotericin B for systemic fungal infections.
    Leenders AC; de Marie S
    Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis.
    Antony S; Dominguez DC; Sotelo E
    J Natl Med Assoc; 2003 Oct; 95(10):982-5. PubMed ID: 14620712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
    Petrikkos GL
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.
    González GM; González G; Najvar LK; Graybill JR
    J Antimicrob Chemother; 2007 Dec; 60(6):1341-6. PubMed ID: 17934204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
    Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
    J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
    Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.